TRACON Pharmaceuticals (NASDAQ:TCON) Gets Neutral Rating from HC Wainwright

HC Wainwright reaffirmed neutral rating on the stock TRACON Pharmaceuticals (NASDAQ:TCON – Free Report) in a report published on Monday, Benzinga reports.

Separately, StockNews.com downgraded shares of TRACON Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, June 27.

Read our latest research report on TRACON Pharmaceuticals

TRACON Pharmaceuticals Share Results

Shares of NASDAQ:TCON opened at $1.11 on Monday. TRACON Pharmaceuticals has a 52-week low of $0.66 and a 52-week high of $14.75. The company has a market cap of $2.97 million, a price-to-earnings ratio of $1.66 and a beta of $1.28. The company has a 50-day simple moving average of $1.49 and a two-hundred day simple moving average of $3.40.

TRACON Pharmaceuticals (NASDAQ:TCON – Get Free Report) last announced its quarterly earnings data on Tuesday, May 14. The biopharmaceutical company reported ($1.33) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.13). The company had revenue of $0.10 million for the quarter. In the same quarter last year, the company posted ($7.20) earnings per share. Research analysts predict that TRACON Pharmaceuticals will post -4 earnings per share for the current year.

TRACON Pharmaceuticals announces dividend

The company also recently declared a dividend, which will be paid on Monday, July 8. Shareholders of record on Friday, June 28 will receive a dividend of $0.045. The ex-dividend date for this dividend is Thursday, June 27. This represents a yield of 40.3%.

TRACON Pharmaceuticals Company Profile

(Download the free report)

TRACON Pharmaceuticals, Inc., a biopharmaceutical company, is focused on the development and commercialization of novel targeted cancer therapies in the United States. Its clinical-stage products include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; and YH001, an investigational humanized monoclonal antibody to cytotoxic T-lymphocyte-associated protein 4 IgG1 that is in Phase I clinical development for the treatment of various cancer indications.

Featured Articles

Get daily news and ratings about TRACON Pharmaceuticals – Enter your email address below to receive a concise summary of the latest news and analyst ratings for TRACON Pharmaceuticals and related companies in MarketBeat.com’s FREE daily newsletter.